ASH 2022 | Incidence of infections in patients with HCL treated with purine and non-purine analogs
Kerry Rogers, MD, The Ohio State University, Columbus, OH, comments on the results of a study investigating the incidence of infections in patients with hairy cell leukemia (HCL) treated with purine and non-purine analogs. Overall, while there was a higher incidence of infections after treatment, there was no statistical difference in the rate of infections between purine and non-purine analogs. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Innate Pharma: Consultancy; Pharmacyclics: Consultancy; Beigene: Consultancy; AstraZeneca: Consultancy, Other: Travel Funding; Novartis: Research Funding; Janssen: Research Funding; AbbVie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding.
